Severe acute respiratory syndrome coronavirus (SARS-CoV) surface glycoprotein, also known as the spike glycoprotein, is encoded by the S gene in SARS-CoV RNA.1 SARS-CoV is a member of the Betacoronavirus genus of viruses and has an approximately 79% sequence identity with SARS-CoV-2, the causative agent of COVID-19.2,3 The spike protein of SARS-CoV and the related viruses SARS-CoV-2 and Middle East respiratory syndrome coronavirus (MERS-CoV) is a transmembrane glycoprotein that assembles into homotrimers on the virus surface and is comprised of an N-terminal S1 subunit, which contains the receptor binding domain (RBD), and a C-terminal S2 subunit, which facilitates fusion between viral and host cell membranes.4,5,6 The 193-amino acid RBD of the SARS-CoV spike protein is a target for neutralizing antibodies.5,7 The SARS-CoV RBD, which spans amino acid residues 318 to 510, is 73% identical to that of SARS-CoV-2 and can bind to human angiotensin-converting enzyme 2 (ACE2), which is the host cell surface receptor for both SARS-CoV and SARS-CoV-2.4,5,6,7 SARS-CoV is the causative agent of SARS, a primarily respiratory illness characterized by fever, cough, shortness of breath, and an approximately 10% fatality rate.3 Cayman's SARS-CoV Surface Glycoprotein S1 Subunit Monoclonal Antibody (Clone 02) can be used for ELISA. The antibody recognizes the S1 subunit to detect the SARS-CoV surface glycoprotein.WARNING This product is not for human or veterinary use.
